CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...